Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled maintenance study of selinexor in TP53 wild-type advanced or recurrent endometrial cancer
MOH_2022-12-05_012216Phase 3Active, not recruiting
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in endometrial cancer (EC) comparing Selinexor maintenance with Placebo maintenance (2 arms). Started Dec 2022; status: active, not recruiting.
02
Drugs
selinexor
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on MOH_2022-12-05_012216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-12-05_012216.